+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Motion Sickness Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Antihistamines, Anticholinergics and Others), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023-2029

  • PDF Icon

    Report

  • 87 Pages
  • April 2023
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5806362
The Asia Pacific Motion Sickness Treatment Market should witness market growth of 3.9% CAGR during the forecast period (2023-2029).

The market should expand as a result of the growing demand for medications that may successfully alleviate the symptoms of motion sickness. This condition is a typical hazard that is connected with extensive foreign travel. In addition, research has found that there is a gender difference in the frequency of motion sickness symptoms in virtual reality (VR), with females experiencing more symptoms than males do. This is because females tend to be more sensitive to motion sickness than males.

The considerable prevalence of motion sickness, particularly among females, is the reason for the projected rise in the demand for anticholinergic and antihistamines medications that inhibit emetic H1-receptors from preventing motion sickness. This is due to the fact that these treatments prevent emetic H1-receptors from activating. Because of this, it is anticipated that the growth of the market will accelerate throughout the time in question.

Moreover, the increasing emphasis of the enterprise on introducing merchandise that addresses and minimizes motion sickness indications is also bolstering market expansion. Introducing a cutting-edge waterproof wearable therapeutic device that provides user-controlled therapy for a range of nausea and vomiting conditions, including those caused by doctor-diagnosed migraines, morning sickness from alcohol withdrawal, anxiety, pregnancy, motion sickness, chemotherapy, and post-operative nausea.

India boasts many natural, historical, cultural, and spiritual treasures. India's spiritual grandeur and heritage attract millions of local and foreign tourists who seek to experience them. Links to sacred or historic locations, people, or events have been instrumental in the growth of several popular tourist destinations, with religion, spirituality, and legacy being significant motivators for travel.

To fully realize the potential of pilgrimage and heritage tourism in India, authorities are striving to integrate development plans for the chosen pilgrimage destinations and heritage cities in collaboration with other stakeholders. Due to these factors, the travel industry in the APAC region is expected to experience growth, and with the rise in tourism, people suffering from motion sickness are expected to increase, which will provide market growth for motion sickness treatment in the region.

The China market dominated the Asia Pacific Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $37.4 Million by 2029. The Japan market is poised to grow at a CAGR of 3.3% during (2023-2029). Additionally, The India market would showcase a CAGR of 4.6% during (2023-2029).

Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).

Scope of the Study

By Drug Class

  • Antihistamines
  • Anticholinergics
  • Others

By Route of Administration

  • Oral
  • Others

By Distribution Channel

  • Drug Store & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

  • Viatris, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • Novartis AG
  • Abbott Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Prestige Consumer Healthcare, Inc.
  • WellSpring Pharmaceutical Corporation (Avista Capital Partners)

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Motion Sickness Treatment Market, by Drug Class
1.4.2 Asia Pacific Motion Sickness Treatment Market, by Route of Administration
1.4.3 Asia Pacific Motion Sickness Treatment Market, by Distribution Channel
1.4.4 Asia Pacific Motion Sickness Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Motion Sickness Treatment Market by Drug Class
3.1 Asia Pacific Antihistamines Market by Country
3.2 Asia Pacific Anticholinergics Market by Country
3.3 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Motion Sickness Treatment Market by Route of Administration
4.1 Asia Pacific Oral Market by Country
4.2 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Motion Sickness Treatment Market by Distribution Channel
5.1 Asia Pacific Drug Store & Retail Pharmacies Market by Country
5.2 Asia Pacific Hospital Pharmacies Market by Country
5.3 Asia Pacific Online Pharmacies Market by Country
Chapter 6. Asia Pacific Motion Sickness Treatment Market by Country
6.1 China Motion Sickness Treatment Market
6.1.1 China Motion Sickness Treatment Market by Drug Class
6.1.2 China Motion Sickness Treatment Market by Route of Administration
6.1.3 China Motion Sickness Treatment Market by Distribution Channel
6.2 Japan Motion Sickness Treatment Market
6.2.1 Japan Motion Sickness Treatment Market by Drug Class
6.2.2 Japan Motion Sickness Treatment Market by Route of Administration
6.2.3 Japan Motion Sickness Treatment Market by Distribution Channel
6.3 India Motion Sickness Treatment Market
6.3.1 India Motion Sickness Treatment Market by Drug Class
6.3.2 India Motion Sickness Treatment Market by Route of Administration
6.3.3 India Motion Sickness Treatment Market by Distribution Channel
6.4 South Korea Motion Sickness Treatment Market
6.4.1 South Korea Motion Sickness Treatment Market by Drug Class
6.4.2 South Korea Motion Sickness Treatment Market by Route of Administration
6.4.3 South Korea Motion Sickness Treatment Market by Distribution Channel
6.5 Singapore Motion Sickness Treatment Market
6.5.1 Singapore Motion Sickness Treatment Market by Drug Class
6.5.2 Singapore Motion Sickness Treatment Market by Route of Administration
6.5.3 Singapore Motion Sickness Treatment Market by Distribution Channel
6.6 Malaysia Motion Sickness Treatment Market
6.6.1 Malaysia Motion Sickness Treatment Market by Drug Class
6.6.2 Malaysia Motion Sickness Treatment Market by Route of Administration
6.6.3 Malaysia Motion Sickness Treatment Market by Distribution Channel
6.7 Rest of Asia Pacific Motion Sickness Treatment Market
6.7.1 Rest of Asia Pacific Motion Sickness Treatment Market by Drug Class
6.7.2 Rest of Asia Pacific Motion Sickness Treatment Market by Route of Administration
6.7.3 Rest of Asia Pacific Motion Sickness Treatment Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Viatris, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental Analysis
7.1.4 Research & Development Expense
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Amneal Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental Analysis
7.3.4 Research & Development Expenses
7.4 Baxter International, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental Analysis
7.4.4 Research & Development Expense
7.5 Novartis AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Abbott Laboratories
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 SWOT Analysis
7.7 Sun Pharmaceutical Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Zydus Lifesciences Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Trials and Approvals:
7.9 Prestige Consumer Healthcare, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.10. WellSpring Pharmaceutical Corporation (Avista Capital Partners)
7.10.1 Company Overview

Companies Mentioned

  • Viatris, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • Novartis AG
  • Abbott Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Prestige Consumer Healthcare, Inc.
  • WellSpring Pharmaceutical Corporation (Avista Capital Partners)

Methodology

Loading
LOADING...